Geographic variation in the onset of decline of male ischemic heart disease mortality in The Netherlands.

Am J Public Health

Department of Public Health and Social Medicine, Erasmus University Rotterdam, The Netherlands.

Published: December 1989

We studied variation in the year of onset of ischemic heart disease mortality decline among regions (n = 39) in the Netherlands. Using loglinear regression methods, a quadratic regression model was fitted to the observed numbers of male deaths in each region in the period 1950-84, controlling for changes in age-structure of populations. The quadratic regression model proved inadequate to describe the mortality experience of females. For the country as a whole, the estimated year of onset of male ischemic heart disease mortality decline is 1973.9. The difference between the earliest and the latest region is almost nine years (1970.0 and 1978.9, respectively). An early onset of decline (less than or equal to 1972) is only found in the urbanized, western part of the country. A later (greater than or equal to 1975) onset of decline is characteristically found in more peripheral regions in the South-West and South-East, as well as in the North. Exploratory correlation and regression analyses show that both average income and percent of population living in larger cities have independent, negative associations with the year of onset of male ischemic heart disease mortality decline. We argue that regional variation in the timing of lifestyle changes is a more plausible explanation of these observations than regional variation in the timing of medical care improvements.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1349765PMC
http://dx.doi.org/10.2105/ajph.79.12.1621DOI Listing

Publication Analysis

Top Keywords

ischemic heart
16
heart disease
16
disease mortality
16
onset decline
12
male ischemic
12
year onset
12
mortality decline
12
quadratic regression
8
regression model
8
onset male
8

Similar Publications

Importance: Nelonemdaz selectively antagonizes the 2B subunit of the N-methyl-d-aspartate glutamate receptor and scavenges free radical species.

Objective: To evaluate whether nelonemdaz enhances the clinical outcomes of patients with acute ischemic stroke undergoing emergent reperfusion therapy.

Design, Setting, And Participants: This multicenter double-blind placebo-controlled randomized phase 3 trial (December 25, 2021, to June 30, 2023, in South Korea) recruited patients with acute ischemic stroke who met the following criteria: National Institutes of Health Stroke Scale score greater than or equal to 8, Alberta Stroke Program Early Computed Tomography score greater than or equal to 4, and endovascular thrombectomy within 12 hours after stroke onset.

View Article and Find Full Text PDF

Ventricular arrhythmias induced by ischemia/reperfusion injury limits the therapeutic effect of early reperfusion therapy for acute myocardial infarction. This study investigated the protective effects of the β2-adrenergic receptor (β2-AR) agonist clenbuterol against ischemia/reperfusion-induced arrhythmias and the underlying mechanism. Anesthetized rats were subjected to 10-min left coronary artery occlusion and 10-min reperfusion in vivo.

View Article and Find Full Text PDF

Platelet membrane-modified exosomes targeting plaques to activate autophagy in vascular smooth muscle cells for atherosclerotic therapy.

Drug Deliv Transl Res

January 2025

Center for Coronary Heart Disease, Department of Cardiology, National Center for Cardiovascular Diseases of China, State Key Laboratory of Cardiovascular Disease, Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 167 Beilishi Rd, Beijing, 100037, China.

Atherosclerosis is one of the leading causes of ischemic cardiovascular disease worldwide. Recent studies indicated that vascular smooth muscle cells (VSMCs) play an indispensable role in the progression of atherosclerosis. Exosomes derived from mesenchymal stem cells (MSCs) have demonstrated promising clinical applications in the treatment of atherosclerosis.

View Article and Find Full Text PDF

Background: Primary percutaneous coronary intervention (PPCI) and fibrinolytic or thrombolytic therapy are common treatments for ST-elevation myocardial infarction (STEMI). Primary percutaneous coronary intervention is more effective than thrombolytic therapy, but fibrinolytic therapy is still a preferable option for patients with limited access to healthcare. Alteplase is a tissue plasminogen activator (tPA) used to treat acute myocardial infarction, acute ischemic stroke, and pulmonary embolism.

View Article and Find Full Text PDF

Background: There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC.

Methods: Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!